8-K: Elicio Therapeutics Reports Phase 2 Study Results, Refines Phase 3 Strategy

Elicio Therapeutics announced Phase 2 AMPLIFY-7P study results for ELI-002 7P in adjuvant pancreatic cancer, which did not meet its primary endpoint in the overall population but showed promise in a specific subgroup.

Summary

• Elicio Therapeutics reported results from its Phase 2 AMPLIFY-7P study for ELI-002 7P in adjuvant mutant KRAS-driven pancreatic ductal adenocarcinoma (PDAC).
• The study did not meet its pre-specified primary endpoint of disease-free survival (DFS) in the intent-to-treat (ITT) population.
• However, post-hoc analyses revealed a stronger DFS benefit in patients with R0 resection (completely resected) and those with lower residual disease.
• In the R0 population (approximately 84% of patients), the hazard ratio for DFS was 0.65 (p=0.048), with a median DFS of 23.8 months versus 12.8 months for observation.
• Mutant KRAS (mKRAS)-specific T cell responses strongly correlated with improved DFS, supporting the biological activity of ELI-002 7P.
• The company plans a refined Phase 3 development strategy focusing on the R0 resected population and potentially extended dosing.
• ELI-002 7P demonstrated a favorable safety and tolerability profile, with no treatment-related discontinuations or deaths.
• Elicio is evaluating strategic financing and partnering opportunities to support future development.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed result; while the primary endpoint was missed, positive signals in a key subgroup and strong biological validation offer a path forward, but the need for financing and the missed primary endpoint temper optimism.

Positives

• Promising efficacy signals observed in the R0 resected patient population (HR 0.65, p=0.048), indicating potential benefit in a significant subgroup.
• Strong correlation between mKRAS-specific T cell responses and improved DFS (HR 0.22, p<0.0001), supporting the drug's biological activity.
• Favorable safety and tolerability profile of ELI-002 7P, with no treatment-related discontinuations or deaths.
• Early DFS separation observed through 9 months during active treatment, suggesting early clinical activity.
• The R0 resected population, representing approximately 84% of enrolled patients, offers a substantial target for Phase 3 development.
• The drug's safety profile supports potential for longer-term administration and combination approaches.

Negatives

• The study did not meet its pre-specified primary endpoint of disease-free survival (DFS) in the intent-to-treat population.
• An imbalance in baseline R1 resection status (19% in ELI-002 7P arm vs. 10% in observation arm) was identified as a known adverse prognostic factor that may have negatively impacted the ITT results.
• Overall survival data remains immature at the time of the Phase 2 analysis.

Risks

• The primary endpoint of DFS was not met in the intent-to-treat population, which could impact regulatory approval and market perception.
• The imbalance in R1 resection status in the ELI-002 7P arm is a known adverse prognostic factor that may have suppressed the overall study results.
• Future clinical development and Phase 3 initiation are subject to securing financing and potential partnering opportunities.
• The company's current cash and cash equivalents are expected to support operations only into the fourth quarter of 2026, indicating a need for capital.

Future Outlook

Elicio Therapeutics plans to refine its Phase 3 development strategy for ELI-002 7P, focusing on R0 resected patients and potentially extended dosing, subject to financing and regulatory alignment. The company is also evaluating strategic financing and partnering opportunities to support future clinical development.

Management Comments

• "While AMPLIFY-7P did not meet its primary endpoint in the intent-to-treat study population, promising efficacy signals in patients with lower residual disease burden sharpen our path forward," said Robert Connelly, President and Chief Executive Officer of Elicio.
• "We identified the patients who benefit most, validated the biology, and demonstrated a favorable safety profile that supports extended dosing in Phase 3. In a disease where no approved options exist after surgery, we believe AMPLIFY-7P demonstrates that ELI-002 7P, an mKRAS-targeted immunotherapy, can generate robust immune responses associated with improved clinical outcomes."
• "The AMPLIFY-7P trial generated important clinical and biological insights that have sharpened our development strategy and strengthened our conviction in ELI-002 7P. The stronger treatment effect observed in completely resected R0 patients, combined with the robust relationship between KRAS-specific T-cell responses and clinical outcomes, supports a clear Phase 3 path focused on patients most likely to benefit from treatment."
• "We look forward to discussing these findings with regulators and believe the results provide important support for the broader application of AMP-enabled immunotherapies across multiple oncogenic drivers," added Christopher Haqq, M.D., Ph.D., Executive Vice President, Head of Research and Development and Chief Medical Officer of Elicio.

Industry Context

StockSavvy.ai notes that the results highlight the challenges in developing adjuvant therapies for pancreatic cancer, a notoriously difficult-to-treat disease. The focus on R0 resected patients and the correlation with immune response align with broader trends in precision medicine and immunotherapy development, aiming to identify patient subgroups most likely to benefit from targeted treatments.

Comparison to Industry Standards

• The AMPLIFY-7P study enrolled 144 patients across 24 U.S. sites, which is a typical size for a Phase 2 study in oncology.
• The primary endpoint of Disease-Free Survival (DFS) is a standard endpoint in adjuvant cancer trials.
• The observed recurrence rates in the observation arm (e.g., >50% within 12 months, ~70-80% within 24 months) are consistent with the high recurrence rates seen in pancreatic cancer patients post-surgery and chemotherapy.
• The lack of approved therapies in the adjuvant setting for PDAC underscores the significant unmet need, a common challenge in many advanced cancer indications.

Stakeholder Impact

• Shareholders: The missed primary endpoint and the need for future financing may impact stock price and investor confidence, while the refined strategy offers potential for future value creation.
• Patients: The study results, while not meeting the primary endpoint, provide hope for a subset of pancreatic cancer patients with R0 resections, and the drug's favorable safety profile is a positive.
• Healthcare Providers: The findings inform treatment decisions for adjuvant pancreatic cancer, particularly highlighting the importance of resection status and potential for immunotherapy in this setting.

Next Steps

• Engage with the FDA for an End-of-Phase 2 meeting to align on the Phase 3 design and regulatory strategy for ELI-002 7P in R0 resected adjuvant mKRAS PDAC.
• Initiate a Phase 3 study in adjuvant PDAC post-FDA alignment, subject to funding.
• Broaden the pipeline across multiple indications, leveraging the clinical foundation from PDAC studies, subject to funding.

Key Dates

Recommendation

The company missed its primary endpoint, which is a significant negative. However, the strong signal in the R0 resected population and the biological validation provide a clear path forward, suggesting potential for future success. The need for financing and the inherent risks in drug development warrant a cautious 'hold' recommendation until further clarity on Phase 3 initiation and funding is available.

Keywords

Elicio Therapeutics, ELI-002 7P, Pancreatic Cancer, Adjuvant Therapy, KRAS Mutation, Phase 2 Study, AMPLIFY-7P, Immunotherapy